DDInter1840 DDInter1760
Trabectedin, also referred as ET-743 during its development, is a marine-derived antitumor agent discovered in the Carribean tunicate _Ecteinascidia turbinata_ and now produced synthetically. Trabectedin has a unique mechanism of action. It binds to the minor groove of DNA interfering with cell division and genetic transcription processes and DNA repair machinery. It is approved for use in Europe, Russia and South Korea for the treatment of advanced soft tissue sarcoma. It is currently under evaluation for the treatment of breast cancer, prostate cancer, in addition to pediatric sarcomas. Both the European Commission and the U.S. Food and Drug Administration (FDA) have approved trabectedin as an orphan drug in soft tissue sarcomas and ovarian cancer. On October 23, 2015, the FDA approved trabectedin, (as Yondelis), for the treatment of specific soft tissue sarcomas.
Telotristat ethyl is a prodrug of telotristat that was approved by the FDA in March 2017 as Xermelo. It was previously referred to as telotristat etiprate, the hippurate salt form; however, the FDA recommends the use of the name of the neutral form rather than that of the salt.[A252937, A252942] Currently, telotristat ethyl is used to treat carcinoid syndrome diarrhea from neuroendocrine tumors that are inadequately controlled by short-acting somatostatin analog (SSA) treatment. Neuroendocrine cells are cells that secrete regulatory peptides and biogenic amines in response to chemical, neural, or other types of stimuli. Neuroendocrine tumors (NET) arising from these cells can therefore secrete chemical mediators into the bloodstream to cause side effects in distant sites, a phenomenon called carcinoid syndrome. The most common peptides and amines secreted by NET are histamines, tachykinins, kallikrein, and serotonin. Overexposure to serotonin can cause severe diarrhea, one of the main clinical symptoms of carcinoid syndrome. Serotonin is metabolized in the urinary metabolite 5-hydroxy indole acetic acid (u5-HIAA), and high levels of u5-HIAA is associated with poor survival outcome in patients with NET. The first line treatment of carcinoid syndrome diarrhea is SSA, but symptoms still reoccur over the course of the disease.
Trabectedin {u} (Compound) binds {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Dasatinib
Dasatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Telotristat ethyl
Trabectedin {u} (Compound) binds {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) and {u} (Gene) is upregulated by {v} (Compound) Crizotinib
Crizotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Telotristat ethyl
Trabectedin {u} (Compound) binds {v} (Gene) SRC
SRC {u} (Gene) is upregulated by {v} (Compound) Dapsone
Dapsone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Telotristat ethyl
Trabectedin {u} (Compound) causes {v} (Side Effect) Alanine aminotransferase increased
Alanine aminotransferase increased {u} (Side Effect) is caused by {v} (Compound) Paclitaxel
Paclitaxel {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Telotristat ethyl
Trabectedin {u} (Compound) causes {v} (Side Effect) Hyperbilirubinaemia
Hyperbilirubinaemia {u} (Side Effect) is caused by {v} (Compound) Octreotide
Octreotide {u} may lead to a major life threatening interaction when taken with {v} Telotristat ethyl
Trabectedin (Compound) binds SRC (Gene) and SRC (Gene) is bound by Dasatinib (Compound) and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl
Trabectedin (Compound) binds SRC (Gene) and SRC (Gene) is bound by Crizotinib (Compound) and SRC (Gene) is upregulated by Crizotinib (Compound) and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl
Trabectedin (Compound) binds SRC (Gene) and SRC (Gene) is upregulated by Dapsone (Compound) and Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl
Trabectedin (Compound) causes Alanine aminotransferase increased (Side Effect) and Alanine aminotransferase increased (Side Effect) is caused by Paclitaxel (Compound) and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl
Trabectedin (Compound) causes Hyperbilirubinaemia (Side Effect) and Hyperbilirubinaemia (Side Effect) is caused by Octreotide (Compound) and Octreotide may lead to a major life threatening interaction when taken with Telotristat ethyl